Dengue virus evolution under a host-targeted antiviral

Journal of Virology

Volumn 89, Issue 10, 2015, Pages 5592-5601

  Plummer, Emily ^a   Buck, Michael D ^a   Sanchez, Marisa ^a   Greenbaum, Jason A ^a   Turner, Julia ^a   Grewal, Rajvir ^a   Klose, Brennan ^b   Sampath, Aruna ^b   Warfield, Kelly L ^b   Peters, Bjoern ^a   Ramstedt, Urban ^b   Shresta, Sujan ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b Unither Virology LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS PROTEIN; ANTIVIRUS AGENT; IMINOSUGAR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DENGUE; EVOLUTION; FEMALE; IN VIVO STUDY; MOUSE; NEXT GENERATION SEQUENCING; NONHUMAN; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VIRAL GENETICS; VIREMIA; VIRUS MUTATION; VIRUS VIRULENCE; 129 MOUSE; ANIMAL; DENGUE VIRUS; DISEASE MODEL; DRUG EFFECTS; GENETIC SELECTION; GENETIC VARIABILITY; GENETICS; HOST PATHOGEN INTERACTION; HUMAN; KNOCKOUT MOUSE; MOLECULAR EVOLUTION; MUTATION; PHYSIOLOGY; VIROLOGY; VIRUS REPLICATION;

DENGUE VIRUS; FLAVIVIRUS; MUS;

ANIMALS; ANTIVIRAL AGENTS; DENGUE; DENGUE VIRUS; DISEASE MODELS, ANIMAL; EVOLUTION, MOLECULAR; GENETIC VARIATION; HOST-PATHOGEN INTERACTIONS; HUMANS; IMINO SUGARS; MICE; MICE, 129 STRAIN; MICE, KNOCKOUT; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; SELECTION, GENETIC; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 84928557326     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00028-15     Document Type: Article

References (46)

1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI. 2013. The global distribution and burden of dengue. Nature 496:504-507. http://dx.doi.org/10.1038/nature12060.
2. Gibbons RV, Vaughn DW. 2002. Dengue: an escalating problem. BMJ 324:1563-1566. http://dx.doi.org/10.1136/bmj.324.7353.1563.
3. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, Moureau A, Saville M, Bouckenooghe A, Viviani S, Tornieporth NG, Lang J. 2012. Protective efficacy of the recombinant, liveattenuated, CYDtetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 380:1559-1567. http://dx.doi.org/10.1016/S0140-6736(12)61428-7.
4. Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, Luong CQ, Rusmil K, Wirawan DN, Nallusamy R, Pitisuttithum P, Thisyakorn U, Yoon IK, van der Vliet D, Langevin E, Laot T, Hutagalung Y, Frago C, Boaz M, Wartel TA, Tornieporth NG, Saville M, Bouckenooghe A, the CYD14 Study Group. 2014. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebocontrolled trial. Lancet 384:1358-1365. http://dx.doi.org/10.1016/S0140-6736(14)61060-6.
5. Chin-inmanu K, Suttitheptumrong A, Sangsrakru D, Tangphatsornruang S, Tragoonrung S, Malasit P, Tungpradabkul S, Suriyaphol P. 2012. Feasibility of using 454 pyrosequencing for studying quasispecies of the whole dengue viral genome. BMC Genomics 13(Suppl 7):S7. http://dx.doi.org/10.1186/1471-2164-13-S7-S7.
6. Ruiz-Jarabo CM, Arias A, Baranowski E, Escarmis C, Domingo E. 2000. Memory in viral quasispecies. J Virol 74:3543-3547. http://dx.doi.org/10.1128/JVI.74.8.3543-3547.2000.
7. Biebricher CK, Eigen M. 2005. The error threshold. Virus research 107: 117-127. http://dx.doi.org/10.1016/j.virusres.2004.11.002.
8. Gnadig NF, Beaucourt S, Campagnola G, Borderia AV, Sanz-Ramos M, Gong P, Blanc H, Peersen OB, Vignuzzi M. 2012. Coxsackievirus B3 mutator strains are attenuated in vivo. Proc Natl Acad Sci U S A 109: E2294-E2303. http://dx.doi.org/10.1073/pnas.1204022109.
9. Vignuzzi M, Andino R. 2012. Closing the gap: the challenges in converging theoretical, computational, experimental and real-life studies in virus evolution. Curr Opin Virol 2:515-518. http://dx.doi.org/10.1016/j.coviro.2012.09.008.
10. Vignuzzi M, Stone JK, Arnold JJ, Cameron CE, Andino R. 2006. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 439:344-348. http://dx.doi.org/10.1038/nature04388.
11. Adiwijaya BS, Herrmann E, Hare B, Kieffer T, Lin C, Kwong AD, Garg V, Randle JC, Sarrazin C, Zeuzem S, Caron PR. 2010. A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants. PLoS Comput Biol 6:e1000745. http://dx.doi.org/10.1371/journal.pcbi.1000745.
12. Verbinnen T, Van Marck H, Vandenbroucke I, Vijgen L, Claes M, Lin TI, Simmen K, Neyts J, Fanning G, Lenz O. 2010. Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing. J Virol 84:11124-11133. http://dx.doi.org/10.1128/JVI.01217-10.
13. Charpentier C, Dwyer DE, Mammano F, Lecossier D, Clavel F, Hance AJ. 2004. Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors. J Virol 78:4234-4247. http://dx.doi.org/10.1128/JVI.78.8.4234-4247.2004.
14. Miura M, Maekawa S, Sato M, Komatsu N, Tatsumi A, Takano S, Amemiya F, Nakayama Y, Inoue T, Sakamoto M, Enomoto N. 2014. Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection. Hepatol Res 44:E360-E367. http://dx.doi.org/10.1111/hepr.12316.
15. Pollara CP, Piccinelli G, Rossi G, Cattaneo C, Perandin F, Corbellini S, Tomasi DD, Bonfanti C. 2013. Nosocomial outbreak of the pandemic Influenza A (H1N1) 2009 in critical hematologic patients during seasonal influenza 2010-2011: detection of oseltamivir resistant variant viruses. BMC Infect Dis 13:127. http://dx.doi.org/10.1186/1471-2334-13-127.
16. Whitby K, Pierson TC, Geiss B, Lane K, Engle M, Zhou Y, Doms RW, Diamond MS. 2005. Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo. J Virol 79:8698-8706. http://dx.doi.org/10.1128/JVI.79.14.8698-8706.2005.
17. Chapel C, Garcia C, Bartosch B, Roingeard P, Zitzmann N, Cosset FL, Dubuisson J, Dwek RA, Trepo C, Zoulim F, Durantel D. 2007. Reduction of the infectivity of hepatitis C virus pseudoparticles by incorporation of misfolded glycoproteins induced by glucosidase inhibitors. J Gen Virol 88:1133-1143. http://dx.doi.org/10.1099/vir.0.82465-0.
18. Block TM, Jordan R. 2001. Iminosugars as possible broad spectrum anti hepatitis virus agents: the glucovirs and alkovirs. Antivir Chem Chemother 12:317-325. http://dx.doi.org/10.1177/095632020101200601.
19. Chang J, Schul W, Butters TD, Yip A, Liu B, Goh A, Lakshminarayana SB, Alonzi D, Reinkensmeier G, Pan X, Qu X, Weidner JM, Wang L, Yu W, Borune N, Kinch MA, Rayahin JE, Moriarty R, Xu X, Shi PY, Guo JT, Block TM. 2011. Combination of alpha-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo. Antiviral Res 89:26-34. http://dx.doi.org/10.1016/j.antiviral.2010.11.002.
20. Qu X, Pan X, Weidner J, Yu W, Alonzi D, Xu X, Butters T, Block T, Guo JT, Chang J. 2011. Inhibitors of endoplasmic reticulum alphaglucosidases potently suppress hepatitis C virus virion assembly and release. Antimicrob Agents Chemother 55:1036-1044. http://dx.doi.org/10.1128/AAC.01319-10.
21. Courageot MP, Frenkiel MP, Dos Santos CD, Deubel V, Despres P. 2000. Alpha-glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulum. J Virol 74:564-572. http://dx.doi.org/10.1128/JVI.74.1.564-572.2000.
22. Perry ST, Buck MD, Plummer EM, Penmasta RA, Batra H, Stavale EJ, Warfield KL, Dwek RA, Butters TD, Alonzi DS, Lada SM, King K, Klose B, Ramstedt U, Shresta S. 2013. An iminosugar with potent inhibition of dengue virus infection in vivo. Antiviral Res 98:35-43. http://dx.doi.org/10.1016/j.antiviral.2013.01.004.
23. Margeridon-Thermet S, Shulman NS, Ahmed A, Shahriar R, Liu T, Wang C, Holmes SP, Babrzadeh F, Gharizadeh B, Hanczaruk B, Simen BB, Egholm M, Shafer RW. 2009. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J Infect Dis 199:1275-1285. http://dx.doi.org/10.1086/597808.
24. Mitsuya Y, Varghese V, Wang C, Liu TF, Holmes SP, Jayakumar P, Gharizadeh B, Ronaghi M, Klein D, Fessel WJ, Shafer RW. 2008. Minority human immunodeficiency virus type 1 variants in antiretroviral-naive persons with reverse transcriptase codon 215 revertant mutations. J Virol 82:10747-10755. http://dx.doi.org/10.1128/JVI.01827-07.
25. Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW. 2007. Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res 17:1195-1201. http://dx.doi.org/10.1101/gr.6468307.
26. Ghedin E, Laplante J, DePasse J, Wentworth DE, Santos RP, Lepow ML, Porter J, Stellrecht K, Lin X, Operario D, Griesemer S, Fitch A, Halpin RA, Stockwell TB, Spiro DJ, Holmes EC, St George K. 2011. Deep sequencing reveals mixed infection with 2009 pandemic influenza A (H1N1) virus strains and the emergence of oseltamivir resistance. J Infect Dis 203:168-174. http://dx.doi.org/10.1093/infdis/jiq040.
27. Fisher R, van Zyl GU, Travers SA, Kosakovsky Pond SL, Engelbrech S, Murrell B, Scheffler K, Smith D. 2012. Deep sequencing reveals minor protease resistance mutations in patients failing a protease inhibitor regimen. J Virol 86:6231-6237. http://dx.doi.org/10.1128/JVI.06541-11.
28. Solmone M, Vincenti D, Prosperi MC, Bruselles A, Ippolito G, Capobianchi MR. 2009. Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen. J Virol 83:1718-1726. http://dx.doi.org/10.1128/JVI.02011-08.
29. Svarovskaia ES, Martin R, McHutchison JG, Miller MD, Mo H. 2012. Abundant drug-resistant NS3 mutants detected by deep sequencing in hepatitis C virus-infected patients undergoing NS3 protease inhibitor monotherapy. J Clin Microbiol 50:3267-3274. http://dx.doi.org/10.1128/JCM.00838-12.
30. Armenia D, Vandenbroucke I, Fabeni L, Van Marck H, Cento V, D'Arrigo R, Van Wesenbeeck L, Scopelliti F, Micheli V, Bruzzone B, Lo Caputo S, Aerssens J, Rizzardini G, Tozzi V, Narciso P, Antinori A, Stuyver L, Perno CF, Ceccherini-Silberstein F. 2012. Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing. J Infect Dis 205:557-567. http://dx.doi.org/10.1093/infdis/jir821.
31. Tsibris AM, Korber B, Arnaout R, Russ C, Lo CC, Leitner T, Gaschen B, Theiler J, Paredes R, Su Z, Hughes MD, Gulick RM, Greaves W, Coakley E, Flexner C, Nusbaum C, Kuritzkes DR. 2009. Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS One 4:e5683. http://dx.doi.org/10.1371/journal.pone.0005683.
32. Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, Welker M, Wincheringer D, Zhou Y, Chu HM, Lin C, Weegink C, Reesink H, Zeuzem S, Kwong AD. 2007. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132:1767-1777. http://dx.doi.org/10.1053/j.gastro.2007.02.037.
33. Perry ST, Prestwood TR, Lada SM, Benedict CA, Shresta S. 2009. Cardif-mediated signaling controls the initial innate response to dengue virus in vivo. J Virol 83:8276-8281. http://dx.doi.org/10.1128/JVI.00365-09.
34. Zellweger RM, Prestwood TR, Shresta S. 2010. Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe 7:128-139. http://dx.doi.org/10.1016/j.chom.2010.01.004.
35. Prestwood TR, Prigozhin DM, Sharar KL, Zellweger RM, Shresta S. 2008. A mouse-passaged dengue virus strain with reduced affinity for heparan sulfate causes severe disease in mice by establishing increased systemic viral loads. J Virol 82:8411-8421. http://dx.doi.org/10.1128/JVI.00611-08.
36. Perry ST, Buck MD, Lada SM, Schindler C, Shresta S. 2011. STAT2 mediates innate immunity to Dengue virus in the absence of STAT1 via the type I interferon receptor. PLoS Pathog 7:e1001297. http://dx.doi.org/10.1371/journal.ppat.1001297.
37. Langmead B, Salzberg SL. 2012. Fast gapped-read alignment with Bowtie 2. Nat Methods 9:357-359. http://dx.doi.org/10.1038/nmeth.1923.
38. Grabherr MG, Haas BJ, Yassour M, Levin JZ, Thompson DA, Amit I, Adiconis X, Fan L, Raychowdhury R, Zeng Q, Chen Z, Mauceli E, Hacohen N, Gnirke A, Rhind N, di Palma F, Birren BW, Nusbaum C, Lindblad-Toh K, Friedman N, Regev A. 2011. Full-length transcriptome assembly from RNA-Seq data without a reference genome. Nat Biotechnol 29:644-652. http://dx.doi.org/10.1038/nbt.1883.
39. Marth GT, Korf I, Yandell MD, Yeh RT, Gu Z, Zakeri H, Stitziel NO, Hillier L, Kwok PY, Gish WR. 1999. A general approach to singlenucleotide polymorphism discovery. Nat Genet 23:452-456. http://dx.doi.org/10.1038/70570.
40. Shresta S, Kyle JL, Snider HM, Basavapatna M, Beatty PR, Harris E. 2004. Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T-and B-cell-dependent immunity are less critical. J Virol 78:2701-2710. http://dx.doi.org/10.1128/JVI.78.6.2701-2710.2004.
41. Prestwood TR, May MM, Plummer EM, Morar MM, Yauch LE, Shresta S. 2012. Trafficking and replication patterns reveal splenic macrophages as major targets of dengue virus in mice. J Virol 86:12138-12147. http://dx.doi.org/10.1128/JVI.00375-12.
42. Brinton MA. 2014. Replication cycle and molecular biology of the West Nile virus. Viruses 6:13-53. http://dx.doi.org/10.3390/v6010013.
43. Asahina Y, Izumi N, Enomoto N, Uchihara M, Kurosaki M, Onuki Y, Nishimura Y, Ueda K, Tsuchiya K, Nakanishi H, Kitamura T, Miyake S. 2005. Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J Hepatol 43:623-629. http://dx.doi.org/10.1016/j.jhep.2005.05.032.
44. Feigelstock DA, Mihalik KB, Feinstone SM. 2011. Selection of hepatitis C virus resistant to ribavirin. Virol J 8:402. http://dx.doi.org/10.1186/1743-422X-8-402.
45. Rong L, Dahari H, Ribeiro RM, Perelson AS. 2010. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2:30ra32. http://dx.doi.org/10.1126/scitranslmed.3000544.
46. Domingo E, Sheldon J, Perales C. 2012. Viral quasispecies evolution. Microbiol Mol Biol Rev 76:159-216. http://dx.doi.org/10.1128/MMBR.05023-11.